Moelis Hires Morgan Stanley’s Gallone for Health-Care Push
(Bloomberg) -- Moelis & Co. said it hired a veteran health-care banker from Morgan Stanley to expand its coverage of the sector in Europe.
Philippe Gallone will join Moelis as a managing director in its global health-care group in London, the advisory firm said in a statement Thursday, confirming an earlier Bloomberg News report. Gallone spent more than 13 years at Morgan Stanley, most recently as the firm's co-head of health-care banking in Europe, the Middle East and Africa, according to the statement.
New York-based Moelis is bolstering its health-care practice in Europe at a time when pharmaceutical companies are searching for solutions to the coronavirus pandemic. A physician by training, Gallone has worked on more than $200 billion of mergers and acquisitions, according to the statement. He helped advise Shire Plc on its $62 billion sale to Japanese drugmaker Takeda Pharmaceutical Co. completed last year.
“The health-care sector globally is facing some of its biggest challenges amid the Covid-19 crisis,” Kenneth Moelis, chief executive officer of Moelis & Co., said in the statement. “These unprecedented conditions, however, are planting the seeds of innovation that will transform the entire health-care system in the years to come.”
Moelis worked with molecular-testing firm Qiagen NV on its 9 billion-euro ($10 billion) takeover by laboratory equipment maker Thermo Fisher Scientific Inc. agreed in March, according to data compiled by Bloomberg. It also advised Austrian vaccine maker Themis Bioscience GmbH on its sale to Merck & Co. announced last month, the data show.
©2020 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
